微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2021, Vol. 13 ›› Issue (2): 195-201.doi: 10.3969/j.issn.1674-5671.2021.02.15

• 临床研究 • 上一篇    下一篇

Gustave Roussy Immune评分评估不可切除食管鳞状细胞癌患者预后的价值

  

  1. 南京医科大学第一附属医院肿瘤放射治疗科
  • 出版日期:2021-04-25 发布日期:2021-04-30
  • 通讯作者: 孙新臣 E-mail：sunxinchen2012@163.com
  • 基金资助:
    国家自然科学基金项目（81874217）

Prognostic value of modified Gustave Roussy Immune Score for patients with unresectable esophageal squamous cell carcinoma

  • Online:2021-04-25 Published:2021-04-30

PDF (PC)

364

赞

摘要： 目的 探讨Gustave Roussy Immune评分（modified GRIm-Score，mGRIm-Score）评估不可切除食管鳞状细胞癌（esophageal squamous cell carcinoma，ESCC）患者预后的价值。方法 收集150例不可切除ESCC患者放化疗前的乳酸脱氢酶、中性粒细胞与淋巴细胞比值、血清白蛋白资料，采用受试者工作特征（ROC）曲线计算最佳截断值并构建mGRIm-Score，根据评分结果分为高mGRIm-Score组和低mGRIm-Score组，Kaplan-Meier法分析生存情况，多因素Cox回归分析独立预后因素。结果 高mGRIm-Score组和低mGRIm-Score组的中位总生存期分别为17.0个月（95%CI：9.6~24.4个月）和48.0个月（95%CI：38.9~57.1个月），中位无进展生存期分别为12.0个月（95%CI：9.5~14.5个月）和25.0个月（95%CI：15.7~52.4个月），差异均有统计学意义（均P<0.05）；多因素分析显示，mGRIm-Score为预测总生存期（HR=1.626，95%CI：1.1~2.5，P=0.024）和无进展生存期（HR=1.539，95%CI：1.0~2.3，P=0.034）的独立预后因素。结论 mGRIm-Score可作为评估不可切除ESCC患者预后的指标。

关键词: 食管鳞状细胞癌, 同步放化疗, 改良Gustave Roussy Immune评分, 乳酸脱氢酶, 血清白蛋白, 中性粒细胞与淋巴细胞比值, 预后

Abstract: Objective  To evaluate the prognosis values of modified Gustave Roussy Immune Score (mGRIm-Score) for patients with unresectable esophageal squamous cell carcinoma (ESCC). Methods The data on lactic dehydrogenase, neutrophil/lymphocyte ratio and serum albumin of 150 patients with unresectable ESCC before chemoradiotherapy were collected . The optimal cut-off values were calculated by receiver operating characteristic(ROC) curves and the mGRIm-Score was constructed. The patients were divided into high mGRIm-Score group and low mGRIm-Score group according to the scoring criteria. Survival was analyzed by Kaplan-Meier method, and independent prognostic factors were analyzed by multivariable Cox regression. Results The median overall survival for high mGRIm-Score group and low mGRIm-Score group were 17.0 months (95%CI: 9.6-24.4 months ) and 48.0 months(95%CI: 38.9-57.1 months), respectively; the median progression-free survival were 12.0 months(95%CI :9.5-14.5 months) and 25.0 months (95%CI: 15.7-52.4 months), respectively, and the differences were statistically significant(all P<0.05). Multivariable analysis suggested that mGRIm-Score was an independent prognostic factor for overall survival (HR=1.626, 95%CI :1.1-2.5, P=0.024) and progression-free survival (HR=1.539, 95%CI :1.0-2.3, P=0.034) . Conclusions The mGRIm-Score before chemoradiotherapy can be used as a comprehensive indicator to evaluate the survival prognosis of patients with unresectable ESCC.

Key words: Esophageal squamous cell carcinoma, Concurrent chemoradiotherapy, Modified Gustave Roussy Immune Score, Lactate dehydrogenase, Albumin, Neutrophil/lymphocyte ratio; , Prognosis

中图分类号: 

  • R735.1